TPG Capital, L.P.
+27.03%
3个月收益率
$6.060
-0.249 (-4.11%)收盘时
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
BDJ is a good buy right now due to its attractive 8.1% dividend yield and a solid 32% increase in dividends over the past decade, indicating strong income potential. Additionally, it is currently trading at an 8.2% discount, which could lead to price appreciation as market confidence improves. The main risk is its recent performance with a 1-day change of -0.31%, suggesting some short-term volatility.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
BDJ is a good buy right now due to its attractive 8.1% dividend yield and a solid 32% increase in dividends over the past decade, indicating strong income potential. Additionally, it is currently trading at an 8.2% discount, which could lead to price appreciation as market confidence improves. The main risk is its recent performance with a 1-day change of -0.31%, suggesting some short-term volatility.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。